论文部分内容阅读
骨髓瘤骨病(MBD)是多发性骨髓瘤(MM)最严重的一种并发症,以多发性溶骨病变及进行性骨质破坏等为特征,其机制的关键在于骨髓瘤细胞激活破骨细胞的同时抑制成骨细胞活性,最终导致骨代谢失衡〔1〕。MBD在MM患者中的发生率超过85%,即便是对化疗有反应的患者也可能逐渐进展
Myeloma bone disease (MBD) is the most serious complication of multiple myeloma (MM). It is characterized by multiple osteolytic lesions and progressive bone destruction. The key point of this mechanism is that myeloma cells activate osteoclasts Cells while inhibiting osteoblast activity, eventually leading to imbalance of bone metabolism 〔1〕. The incidence of MBD in MM patients exceeds 85%, and even patients who respond to chemotherapy may progressively progress